 | |
| Clinical data | |
|---|---|
| Other names | MPHP |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H25NO |
| Molar mass | 259.393 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
4'-Methyl-α-pyrrolidinohexiophenone (MPHP) is astimulant compound which has been reported as a noveldesigner drug.[1][2][3] It is closely related topyrovalerone, being simply its chain-lengthenedhomologue. In the pyrrolidinophenone series, stimulant activity is maintained so long as the positions of thearyl,ketone andpyrrolidinyl groups are held constant, while the alkyl backbone can be varied anywhere between three and as many as seven carbons,[4] with highest potency usually seen with the pentyl or isohexyl backbone, and a variety of substituents are tolerated on the aromatic ring.[5]
In 2010 a group of researchers from the Institute of Forensic Medicine, University Hospital Jena, Germany concluded that MPHP can lead to serious poisoning with toxic liver damage andrhabdomyolysis.[6]
In the United States, MPHP is aSchedule I Controlled Substance.[7] Sweden's public health agency suggested to classify MPHP as narcotic on June 1, 2015.[8]
